The medtech industry is a step closer to getting clear guidance from the Food and Drug Administration on using social networking sites such as Facebook, Twitter, LinkedIn and YouTube to promote its products.
The agency has scheduled a two-day public hearing, beginning today, to get comment from industry on issues relating to FDA-regulated products such as adverse event reporting, corporate responsibility of user-generated content and fair balance1...
Please login to read the full article.
